NICE turns down Novartis’ Adakveo
Trial results and cost-effectiveness are too uncertain for NHS use, the Institute said
Read More
Tag: Crizanlizumab
Eleven medicines backed for EU approval
Recommendations include the first antibody-drug conjugate for multiple myeloma patients with limited treatment options
Read More
Novartis’ crizanlizumab granted FDA Breakthrough Therapy
US regulators have granted Novartis’ crizanlizumab (SEG101) Breakthrough Therapy designation for the prevention of vaso-occlusive crises in patients with sickle cell disease.
Read More
Novartis crizanlizumab shows promise in sickle cell anaemia
A new analysis has shown that Novartis’ crizanlizumab reduced the number of patients with sickle cell disease experiencing a pain crisis.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
